British Columbia-based Symvivo Corporation has enrolled the first participant in a Phase 1 clinical trial of its COVID-19 vaccine candidate. The individual is in Australia, as the trial is being conducted with a Brisbane-based partner. The vaccine candidate is unique among the many COVID-19 vaccines under development as it is taken as an oral capsule rather than by injection, and it can be stored and transported at room temperature.